Amigo....I get that concerning pre-clinicals. My point was, at the time of the announcement, the company claimed the pre-clincials worked and the announcement stated they augmented Rexista formula with Podras. they then later stated they redid another phase 1 trial. one would assume if a previous document stated they augmented the formula with Podras and they then redid a phase 1 that the new phase 1 included Podras. the subsequent HAL and food safety studies, they released just stated that Rexista was BE and didn't have a food effect. They also only held one IND. which included Podras. they never stated they did two separate sets of studies and both met BE and food effect. therefore, its an assumption on my part that the formula was indeed augmented with Podras in the subsequent studies. this would allow the company the ability to either keep it in the formula or just take it out depending on if the future partner was interested.
I agree, maybe asking the question is the best way to settle the issue. I will wait until after the pending news. Today we are at day 69. I am sure things are buzzing there. this isn't a dire need to know at this juncture.
News 
Market Data 
Discover 
AI
